麻豆视频传媒在线播放,亚洲欧美综合精品久久成人网,一本大道久久亚洲一区

規(guī)格	庫(kù)存	目錄價(jià)	會(huì)員專(zhuān)享價(jià)	數(shù)量
10 mg	3-5days	￥600.00	登錄后可見(jiàn)	- +
25 mg	3-5days	￥980.00	登錄后可見(jiàn)	- +
50 mg	3-5days	￥1568.00	登錄后可見(jiàn)	- +

規(guī)格

庫(kù)存

目錄價(jià)

會(huì)員專(zhuān)享價(jià)

數(shù)量

10 mg

3-5days

￥600.00

登錄后可見(jiàn)

- +

25 mg

3-5days

￥980.00

登錄后可見(jiàn)

- +

50 mg

3-5days

￥1568.00

登錄后可見(jiàn)

- +

基本信息

英文名稱(chēng)	Crizotinib hydrochloride \| PF-02341066 hydrochloride
中文名稱(chēng)	鹽酸克里唑替尼
CAS號(hào)	1415560-69-8
分子式	C21H23Cl3FN5O
分子量	486.80
外觀	Yellow to brown powder
儲(chǔ)存條件	4°C, sealed storage, away from moisture

產(chǎn)品詳情

Crizotinib HCl (formerly known as PF-02341066 hydrochloride; trade name: Xalkori) is a potent, orally bioavailable small molecule inhibitor of c-Met and ALK, with IC50 values of 11 nM and 24 nM in assays involving cells, respectively. In the US, crizotinib is licensed for the treatment of non-small cell lung cancer (NSCLC). It is also being investigated in clinical trials for safety and effectiveness in the treatment of neuroblastoma, anaplastic large cell lymphoma, and other advanced solid tumors in both adults and children. Crizotinib inhibits the activation of the MET signaling pathway and the membrane receptor MET, which in susceptible tumor cell populations may prevent tumor cell growth, migration, invasion, and angiogenesis.

相關(guān)文獻(xiàn)

An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms.

PMID: 17483355 DOI: 10.1158/0008-5472.CAN-06-4443

PMID: 21812414 DOI: 10.1021/jm2007613

Mol Cancer Ther. 2007, 6(12 Pt 1), 3314-3322.

相關(guān)產(chǎn)品